About Us

Company Leadership

Executive Management

Andrew Joiner, President, CEO & Director

Mr. Joiner was appointed CEO in October of 2012 and brings to Tepha 25 years of medical device experience including Sales, Marketing, General Management, and Executive Leadership.  Prior to joining Tepha, Mr. Joiner was Vice President and General Manager of Commercial Operations, at Tornier, a global provider of Extremity Orthopedics from April of 2008, to January of 2012. Previous to joining Tornier, Mr. Joiner served at American Medical Systems from December of 2000 to April 2008, in various executive leadership roles including General Manager, Women’s Health. Previous to his tenure at American Medical Systems, Mr. Joiner spent ten years at U.S. Surgical.

John Hartnett, Executive Vice President, & COO

Mr. Hartnett has over 20 years of experience in medical devices, and was formerly the Director of Business Development at Boston Scientific. His experiences range from product sales, product marketing, business development, and strategic planning for a variety of medical device product ranges. He holds an M.B.A. from Boston University.

Said Rizk, Chief Innovations Officer and Sr. Vice President of Manufacturing and Process Technologies

Mr. Rizk is a leading expert in the development of processes to produce new medical fibers and devices, and joined Tepha in 2003. He has over 20 years of experience in the medical device industry. He developed and commercialized numerous products at Ethicon, Inc., a division of Johnson and Johnson. At U.S. Surgical, Inc., Mr. Rizk was Sr. Director of Engineering; and in this capacity he helped make U.S. Surgical into a suture company.

David Martin, Ph.D., Chief Scientific Officer and Sr. Vice President of Research & Development

Dr. Martin is an expert on the development of medical applications with the Company’s PHA biomaterials and their manufacture, and has been with Tepha since its inception. He has over 12 years of R&D experience with the Company’s biomaterials, and previously worked at Metabolix on various aspects of PHA biochemistry, synthesis, and applications development. He completed a Ph.D. in organic chemistry at Stanford University in 1994.

Board of Directors

Richard Emmitt, Director

Mr. Emmitt is a Managing Director of The Vertical Group, a New Jersey-based medical device venture capital partnership that succeeded the venture capital activities of F. Eberstadt & Co. Mr. Emmitt has been recognized as one of the leading experts on the healthcare industry, with more than thirty years’ experience in healthcare-related venture capital, investment research, and investment banking. He currently serves on the board of several public and private medical device companies including BioSet, ENTrigue Surgical, Galil Medical, Incumed, and Tornier. During the past five years, Mr. Emmitt previously served on the board of directors of American Medical Systems, ev3 , Micro Therapeutics and Wright Medical Group.. Mr. Emmitt was also involved in the successful development of SciMed Life Systems and Xomed Surgical Products, which were ultimately acquired by Boston Scientific and Medtronic, respectively. He holds an M.B.A from The Rutgers School of Business and a B.A. from Bucknell University.

Edward Giles, Director

Mr. Giles is a Special Limited Partner of The Vertical Fund, and Chairman of The Vertical Group. From 1979 through 1985, he was President of F. Eberstadt & Co., and then Vice Chairman of Eberstadt Fleming until 1988. Mr. Giles received a B.Ch.E. from Princeton University in 1957 and a S.M. (industrial management) from the Massachusetts Institute of Technology in 1959. He is also a board member of Ventana Medical Systems and Metabolix, Inc.

Anthony Sinskey, Sc.D., Director

Dr. Sinskey is a Professor of Microbiology and Engineering Systems at the Massachusetts Institute of Technology, and Professor of Health Sciences & Technology at the Harvard-MIT Division of Health Sciences & Technology. Dr. Sinskey also holds positions as Co-Director of the Malaysia-MIT Biotechnology Partnership Program and as Faculty Director of the Center for Biomedical Innovation. He is widely recognized for pioneering multidisciplinary approaches to metabolic engineering of biodegradable polymers, natural products (amino acids, antibiotics), and energy dense fuels. Dr. Sinskey has helped to found many successful biotechnology companies including Genzyme and Aspen Technology. Dr. Sinskey is a co-founder and member of the Board of Directors at Metabolix, Merrimack Pharmaceuticals, and Tepha and a consultant to several chemical and biotechnology companies. Dr. Sinskey received a Sc.D. from Massachusetts Institute of Technology and a B.S. from the University of Illinois.

Matthew Strobeck, Ph.D., Director

From June 2008 to October 2011, Dr. Strobeck was a partner, member of the management committee and member of the advisory board of Westfield Capital Management, an investment firm with approximately $15 billion in assets under management. Dr. Strobeck organized and completed the repurchase of Westfield in 2008 from Boston Private Bank, and prior to this transaction he was a member of the investment team. Dr. Strobeck received a B.S. from St. Lawrence University, a Ph.D. from the University of Cincinnati, an S.M. from the Harvard University-MIT Health Sciences Technology Program and an S.M. from the MIT Sloan School of Management.

Simon Williams, Ph.D., Director

Dr. Williams is the founder of Tepha and is a cofounder of Metabolix, Tepha’s sister company, and served on the Metabolix Board of Directors since its formation in 1992 until 2006. Dr. Williams led the spinout of Tepha from Metabolix. Prior to co-founding Metabolix, Dr. Williams was a lecturer in organic chemistry at Manchester University in England, and a visiting scientist and NATO postdoctoral fellow at M.I.T. He completed a Ph.D. in organic chemistry at Cambridge University, England.